Advancing Next-Generation Biotherapeutics: A Unified Platform for Automated Developability Assessment and AI-Driven Predictive Modeling

The development of next-generation biotherapeutics, including multispecific antibodies, antibody-drug conjugates (ADCs), and complex modalities like RNA lipid nanoparticles, introduces significant developability and manufacturability challenges. Late-stage liabilities such as aggregation, formulation instability, and poor expression yield frequently compress timelines, create downstream bottlenecks, and lead to costly failures.

In this webinar, Jana Hersch, Head of Science at Genedata, will present a scalable enterprise AI platform that enables continuous developability assessment from early discovery through Chemistry, Manufacturing, and Controls (CMC). The system automates the capture, standardization, and analysis of multi-parametric assay data, including SEC, DLS, DSF, and mass spectrometry. Building on this foundation, the platform enables data modeling and AI-driven analytics and connects molecular context, experimental results, and predictive insights across the developability lifecycle. Identification of risk patterns helps teams intervene early, ultimately improving both efficiency and decision quality throughout biotherapeutic development.